scholarly journals Preventive effect of Macaranga barteri Mül Arg. (Euphorbiaceae) aqueous leaf extract on amiodarone induced non-alcoholic fatty liver disease in rats

2021 ◽  
pp. 131-139
Author(s):  
Nomane Bernard Goze ◽  
Kouakou Léandre ◽  
OUSSOU N’Guessan Jean-Baptiste OUSSOU N ◽  
EHILE Ehilé Hervé ◽  
KOFFI Kouassi Bah Abel ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Hepatic Triglyceride ◽  
Preventive Effect ◽  
Alcoholic Fatty Liver ◽  
Group 2 ◽  
Hematological And Biochemical Parameters ◽  
Alcoholic Fatty Liver Disease

Macaranga barteri is a plant used in traditional medicine to treat non-alcoholic fatty liver disease. However, its potential against hepatic steatosis has not been scientifically proven yet. This work aimed to investigate the preventive effect of the aqueous extract of Macaranga barteri leaves (AEMb) on hepatic steatosis experimentally induced with amiodarone in rats. 36 rats were divided into 6 groups of 6 rats each. Group 1, the non-intoxicated group and Group 2, used as controls were pretreated with distilled water (10 ml/kg b.w.). Group 3 received silymarin at 100 mg/kg b.w. while Groups 4, 5 and 6 were pretreated with AEMb at doses of 125, 250 and 500 mg/kg b.w. respectively. The weights of the rats were monitored during the experimentation. After 7 days of daily pretreatment with the different substances, rats of groups 2 to 6 were administered intraperitoneally amiodarone (200 mg/kg bw) three times daily for seven other consecutive days. At the end of the experiments, blood samples were collected on fasted and anesthetized rats kept in dried and EDTA tubes in order to assess some hematological and biochemical parameters and also rats livers were removed for gross observation and hepatic triglyceride assessment. The results revealed that AEMb and silymarin inhibited the weight loss induced by amiodarone and even favored weight gain. The reduction of heamatological indices (leukocytes and leukocyte indices, erythrocytes and erythrocyte indices (MCV, MCH and MCHC), hemoglobin, hematocrit and thrombocytes) by amiodarone was impeded in AEMb treated rats. AEMb significantly reduced (p <0.001) lipid profile parameters (plasma triglycerides, cholesterols (LDL, HDL and total)) augmented by amiodarone. Increased hepatic parameters (alkaline phosphatase, bilirubins (total and conjugated), transaminases (AST and ALT)) elicited by amiodarone were restored by AEMb pretreatment while decreased HDL values were normalized as well. Silymarin and AEMb also restored livers appearance and hepatic triglyceride. In conclusion, AEMb have a real preventive potential against amiodarone induced-hepatic steatosis in rats.

scholarly journals Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model

2019 ◽  
Vol 20 (9) ◽  
pp. 2325 ◽  
Author(s):  
Hua Li ◽  
Wonbeak Yoo ◽  
Hye-Mi Park ◽  
Soo-Youn Lim ◽  
Dong-Ha Shin ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Fatty Acid Synthase ◽  
Regulatory Element ◽  
Diet Group ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Arazyme, a metalloprotease from the spider Nephila clavata, exerts hepatoprotective activity in CCL4-induced acute hepatic injury. This study investigated the hepatoprotective effects in high-fat diet (HFD)-induced non-alcoholic fatty liver disease-like C57BL/6J mice. The mice were randomly divided into four groups (n = 10/group): the normal diet group, the HFD group, the arazyme group (HFD with 0.025% arazyme), and the milk thistle (MT) group (HFD with 0.1% MT). Dietary supplementation of arazyme for 13 weeks significantly lowered plasma triglyceride (TG) and non-esterified fatty acid levels. Suppression of HFD-induced hepatic steatosis in the arazyme group was caused by the reduced hepatic TG and total cholesterol (TC) contents. Arazyme supplementation decreased hepatic lipogenesis-related gene expression, sterol regulatory element-binding transcription protein 1 (Srebf1), fatty acid synthase (Fas), acetyl-CoA carboxylase 1 (Acc1), stearoyl-CoA desaturase-1 (Scd1), Scd2, glycerol-3-phosphate acyltransferase (Gpam), diacylglycerol O-acyltransferase 1 (Dgat1), and Dgat2. Arazyme directly reduced palmitic acid (PA)-induced TG accumulation in HepG2 cells. Arazyme suppressed macrophage infiltration and tumor necrosis factor α (Tnfa), interleukin-1β (Il1b), and chemokine-ligand-2 (Ccl2) expression in the liver, and inhibited secretion of TNFα and expression of inflammatory mediators, Tnfa, Il1b, Ccl2, Ccl3, Ccl4, and Ccl5, in PA-induced RAW264.7 cells. Arazyme effectively protected hepatic steatosis and steatohepatitis by inhibiting SREBP-1-mediated lipid accumulation and macrophage-mediated inflammation.

Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis

2019 ◽  
Vol 29 (7) ◽  
pp. 3564-3573 ◽  
Author(s):  
Jiulian Gu ◽  
Shousheng Liu ◽  
Shuixian Du ◽  
Qing Zhang ◽  
Jianhan Xiao ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes

2014 ◽  
Vol 31 (9) ◽  
pp. 1039-1046 ◽  
Author(s):  
S. J. Jenks ◽  
B. R. Conway ◽  
T. J. Hor ◽  
R. M. Williamson ◽  
S. McLachlan ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
Fatty Liver Disease ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease
Sign in / Sign up

Export Citation Format

Share Document